Deep phenotyping of patient cohorts with thoracic malignancies by Klotz, Laura Valentina




Comprehensive Pneumology Center 
of the Helmholtz Center Munich, Germany 
 
and  
Department of Thoracic Surgery 











zum Erwerb des Doctor of Philosophy (Ph.D.) 




































Supervisor:    Prof. Dr. Dr. Rudolf A. Hatz 
 
Second evaluator:  Dr. Georgios T. Stathopoulos 
 
 





Date of oral defense:       12.01.2021 
 
 







I hereby declare, that the submitted thesis entitled 
 
 
“Deep phenotyping of patient cohorts with thoracic malignancies” 
 
 
is my own work. I have only used the sources indicated and have not made unauthorized use 
of services of a third party. Where the work of others have been quoted or reproduced, the 
source is always given. 
 
I further declare that the submitted thesis or parts thereof have not been presented as part 





Heidelberg, 12.01.2021   Laura Klotz 
 
Place, date     Signature of doctoral candidate 
3
   
 
 
TABLE OF CONTENTS 
 
Affidavit           3 
Table of contents          4 
List of abbreviations          5 
Publications included in the thesis        6 
 
Introductory summary         7 
1.  Lung cancer          7 
2.     Challenges in the treatment of lung cancer      7 
3.     Aim of the research project        8 
3.1     Important aspects of the research project      9 
4.    Aim of the second research project        10 
4.1     Important aspects of the research project      11 
5.     Contribution of the PhD candidate          12 
 
Publication I           13 
Publication II           42 
 
References           50 
Acknowledgement          53 












   
 
 
LIST OF ABBREVIATIONS 
 
ALK   Anaplastic Lymphoma Kinase 
COPD   Chronic Obstructive Pulmonary Disease 
EGFR   Epidermal Growth Factor Receptor 
EML4   Echinoderm Microtubule-associated protein-Like 4 
GLAD   Gauting locoregional Lung ADenocarcinoma cohort 
IASLC   International Association for the Study of Lung Cancer 
KRAS   Kirsten rRAt Sarcoma oncogene 
LACE   Lung Adjuvant Cisplatin Evaluation study 
LADERS  Lung Adenocarcinoma DEath Risk Score 
LADC   Lung ADenoCarcinoma 
N   lymph node (TNM staging system) 
NSCLC  Non-Small Cell Lung Cancer 
SCLC   Small Cell Lung Cancer 
TNM   Tumor Nodus Metastasis (Staging System) 
5
   
 
 





Comprehensive clinical profiling of the Gauting locoregional lung adenocarcinoma 
donors. 
Klotz LV, Courty Y, Lindner M, Petit-Courty A, Stowasser A, Koch I, Eichhorn ME, Lilis I, 
Morresi-Hauf A, Arendt KAM, Pepe M, Giopanou I, Ntaliarda G, Behrend SJ, Oplopoiou M, 
Gissot V, Guyetant S, Marchand-Adam S, Behr J, Kaiser JC, Hatz RA, Lamort AS, 
Stathopoulos GT.  





Prognostic relevance of regional lymph-node distribution in patients with N1-positive 
non-small cell lung cancer: A retrospective single-center analysis. 
Eichhorn F, Klotz LV, Muley T, Kobinger S, Winter H, Eichhorn ME. 
























1. Lung cancer 
 
Lung cancer is the second leading cause of cancer death in women and the most common 
cause of cancer death in men [1]. Smoking still remains the predominant cause of lung 
cancer development, but in addition environmental factors like air pollution, radon, and 
asbestos as well as genetic susceptibility are of increasing relevance [2]. Lung cancer can be 
histologically classified as Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung 
Cancer (SCLC). In Germany, about 80% of all lung cancer cases are NSCLC [3].  
NSCLC is a heterogeneous tumor entity with its two main subtypes of squamous cell 
carcinoma and adenocarcinoma. In recent years, lung adenocarcinoma (LADC) has become 
the most common histologic subtype of lung cancer [4, 5]. LADC is responsible for 
approximately 650.000 deaths per year worldwide and represents the most deadly form of 
human cancer [6]. Regardless of the smoking status, the incidence of LADC is still increasing 
worldwide [1, 6, 7]. In addition, LADC represents the most frequent histological subtype of 
lung cancer in women, younger people, and never smokers [7]. Therefore, there is an 
important need to understand the reasons for the development of LADC by phenotyping and 
genetically characterizing the disease to be able to develop personalized and effective 
treatment strategies. 
As described, known causes of LADC are smoking and radon exposition, but since this 
deadly disease is getting more frequent in never-smokers and young patients, other relevant 
factors like genetic mutations or environmental influences have to be causative. In recent 
years, so called driver mutations have been identified in NSCLC, primarily in never smokers 
or ex-smokers with LADC. The two most relevant driver mutations in the clinical routine are 
a) activating mutation of the epidermal growth factor receptor gene (EGFR) and b) fusion of 
the echinoderm microtubule-associated protein-like 4 (EML4) gene with the anaplastic 
lymphoma kinase gene (ALK) [8]. 
 
 
2. Challenges in the treatment of lung cancer 
 
Although multiple approaches concerning cancer prevention and early detection of cancer 
development have been established, only about 15% of the patients diagnosed with 
locoregional LADC have the option to undergo surgical tumor resection with curative intent if 
distant or contralateral metastases can be ruled out [9, 10]. This is due to a long 
asymptomatic period of lung cancer growth until late in the disease development. Moreover, 
pulmonary symptoms of many smokers are often non-specific, leading to a clinically relevant 
delay of lung cancer diagnosis and start of adequate cancer treatment [11]. 
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Unfortunately, there is a relevant proportion of about 10 to 15% of the patients suffering from 
locoregional tumor recurrence after complete surgical resection of an initially early-stage 
NSCLC [12]. Furthermore many patients suffer from distant metastases during follow-up, 
resulting in a limited prognosis [13]. Additional adjuvant chemotherapy can reduce tumor 
recurrence following surgery for localized lung cancer with a tumor size larger than four 
centimeters or lymph node metastases [14]. The Lung Adjuvant Cisplatin Evaluation (LACE) 
study investigated the effect of platinum-based adjuvant chemotherapy following resection of 
early stage NSCLC and identified an increased 5-year survival of 5.4% for patients receiving 
adjuvant chemotherapy [15]. Nevertheless, due to the individual therapeutic response of 
each patient to chemotherapy, it remains impossible to predict which patients will benefit 
from adjuvant chemotherapy [15]. 
 
 
3. Aim of the research project 
 
Current molecular findings indicate that LADC might be a different disease entity within the 
heterogeneous group of NSCLC [16]. To date, the cell of origin and different relevant cellular 
processes during carcinogenesis concerning LADC are still under debate [17]. Airway cells 
play a central role for lung regeneration and carcinogenesis because epithelial 
developmental steps seem to be linked with important oncogenic signaling pathways which 
are involved in the development of LADC [17-19].  
Although novel mutations are constantly discovered by extensive analyses of tumor tissue, 
their phenotypic impact and especially their potential clinical significance are largely 
ambiguous [20, 21]. To help address this issue, global genomic information of carefully 
clinically phenotyped patient cohorts with LADC would be invaluable. A precise phenotyping 
might help to improve the knowledge of the complex pathobiology of LADC and to optimize 
personalized treatment strategies [22]. Possible associations of clinical variables of LADC 
patients with molecular biomarkers have not been extensively analyzed in large patient 
cohorts.  
A detailed correlation of the phenotype and genotype of LADC may contribute to improve 
personalized targeted therapy for patients with defined oncogenic driver mutations [23]. 
Based on this, we aim to identify associations of patient characteristics and molecular 






   
 
 
3.1 Important aspects of the research project 
 
In the publication “Comprehensive clinical profiling of the Gauting locoregional lung 
adenocarcinoma donors”, we analyzed substantial amounts of clinical information of 366 
patients undergoing surgery for locoregional LADC with curative intent at the Lung Clinic 
Gauting. Clinical parameters were reported with focus on patient characteristics, 
perioperative data and follow-up information concerning recurrence-free and overall survival 
[24]. Based on this cohort, clinical parameters could be correlated to individual pathological 
and genetic alterations of the tumor tissue and the tumor environment. For validation of the 
surgical cohort, clinical findings were evaluated in another cohort from France and in 
comparison to previous studies. 
 
In our analysis, we were able to confirm the high frequency of LADC in women, never 
smokers, and ex-smokers [25]. The data underlines that smoking is closely correlated with 
the development of LADC and COPD, suggesting that active smoking promotes the ongoing 
tumor growth in lung tissue [26, 27]. Initial results from our surgical cohort of patients with 
locoregional LADC support the value of the revised 7th TNM staging system and of the LADC 
histologic classification system [28-30].  
We could show novel clinical associations such as the predominance of these tumors to 
arise in the right upper lobe for smokers. Solid tumor subtype is more frequent in smokers 
while never smokers frequently show acinar tumor histology [24]. Smoking status is 
negatively associated with lymph node involvement, pleural spread, and bone metastases 
during follow-up [24]. Interestingly, overall survival was significantly reduced in patients 
younger than 45 years when compared to patients with an age between 45 and 65 years. 
Possibly, younger patients develop a more aggressive tumor type which might be due to 
germline tumor suppressor loss. This hypothesis will be tested and analyzed in the matching 
LADC tumor tissue in upcoming projects [31]. 
 
For the first time, our work substantiated that time from diagnosis to surgery represents a 
crucial interval regarding overall survival, enhancing the aggressive growth pattern of LADC 
and the important value of surgery in a timely manner for the treatment of locoregional 
disease. In addition, we identified differences in the temporal development of organ-specific 
metastases, probably comparable to biphasic metastatic patterns of other solid tumors like 
colorectal or gynecological cancer [32]. According to this, we could demonstrate that pleural 
metastases and pleural effusion develop earlier during follow-up than ipsilateral or 
contralateral pulmonary metastases [24]. 
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Using clinical characteristics of the individual patient and follow-up data regarding disease-
free and overall survival, different clinical factors such as the adverse effects of age for 
patients younger than 45 or older than 65 years, FEV1 below 80% of the age-appropriate set 
point, and delayed resection on survival defined as surgery later than 60 days after 
diagnosis, could be identified to substantially affect prognosis. In accordance with the 
described clinical work and our research interest, we utilized the detailed and valuable 
clinical information from our cohort for the establishment of a new lung adenocarcinoma 
death risk score (LADERS) in order to predict overall survival after surgery for locoregional 
disease [24]. This clinical score is clearly structured without the need for additional clinical 
tests, and represents an accurate clinical classification system to assess overall survival for 
patients with locoregional LADC. 
 
The independent predictors of survival were identified by proportional hazards Cox 
regression analysis. Based on this, the locoregional lung adenocarcinoma death risk score 




(95% confidence interval) Probability 
Hazard 
points 
Age < 45 or > 65 years 4.12(2.35-7.23) 0.0000008 3 
FVC < 80% predicted 2.13(1.25-3.63) 0.0054374 1 
DLCO/VA  < 70% predicted 2.62(1.60-4.29) 0.0001292 2 
N2 3.56(2.20-5.76) 0.0000002 2.5 
N3 8.65(1.10-68.21) 0.0406576 7.5 
Time to surgery > 60 days 4.04(2.07-7.88) 0.0000408 3 
Solid histologic subtype 2.09(1.27-3.43) 0.0035422 1 
LADERS 0-20 
 
The LADC risk score was able to predict overall survival more precisely compared to the 7th 
TNM staging system. The 7th TNM staging system was still superior in predicting recurrence-
free survival. Consequently, a combination of detailed clinical information together with 
histopathological analysis represents a promising approach to uncover novel genome-
phenome links in LADC and might achieve valuable insights into the mechanisms of 
carcinogenesis in the respiratory tract. 
 
 
4. Aim of the second research project 
 
The work within the manuscript “Prognostic relevance of regional lymph-node distribution in 
patients with N1-positive non-small cell lung cancer: A retrospective single-center analysis” 
was conducted with the aim to specify the classification system of lung cancer staging 
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concerning lymph node involvement [33]. The current staging system has been developed 
and improved by the International Association for the Study of Lung Cancer (IASLC) based 
on a large patient cohort mainly from Asian countries [34]. Since it cannot be ruled out that 
the prognostic factors for survival are different in Asian and European patients, the 
prognostic factors for survival should be validated in a large cohort of patients from Europe 
with locoregional lung cancer and involvement of hilar lymph nodes (N1 positive) [33]. 
According to this, we analyzed 317 patients undergoing surgery for lung cancer with curative 
intent at the Thoraxklinik Heidelberg. Clinical associations between the presence of lymph 
node metastases in the peripheral or hilar zone (N1 position) of the resected lung lobe and 
overall survival were retrospectively analyzed. 
 
 
4.1 Important aspects of the research project 
 
In the publication “Prognostic relevance of regional lymph-node distribution in patients with 
N1-positive non-small cell lung cancer”, we retrospectively analyzed clinical data of patients 
with N1-positive NSCLC undergoing curative-intent thoracic surgery. In case of advanced 
locoregional disease with tumor metastases in hilar (lymph node positions 10-11) and/ or 
peripheral (lymph node positions 12-14) lymph nodes of the N1 compartment, patients with 
LADC have a poor prognosis compared to patients without lymph node metastases. 
According to the different N-descriptors of the current TNM staging system, overall survival of 
the individual patient with locoregional disease is dependent on the presence of hilar or 
mediastinal lymph node metastases [34]. However, significant differences concerning 
disease-free and overall survival have been identified for lung cancer patients within the 
same N-category [35]. Analysis of the IASLC cohort of N1-positive patients revealed a 
decrease of overall survival in correlation with an increasing number of metastatic lymph 
nodes. Consequently, the IASLC committee gave the recommendation to subdivide N1-
positive lung cancer patients into N1a (single lymph node position involved) and N1b (more 
than one position involved) in the upcoming TNM staging classification [34]. We were able to 
confirm the differences concerning overall survival for patients with pathologically confirmed 
N1a and N1b lymph node involvement following curative-intent surgery. Due to the fact that 
there is only limited European patient data available in the IASLC database with only 544 N1 
patients from two European countries, our patient cohort with 317 patients displays an 
important and valuable addition to published clinical data [28, 34]. For detailed classification 
of lymph node involvement and to validate possible correlations to disease-free and overall 
survival, Rusch and colleagues proposed the classification of lymph nodes into “zones,” 
which has been adopted by the IASLC lymph node map [36]. According to this proposal, we 
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could verify that lymph node metastases in more than one zone were associated with a poor 
overall survival compared to lymph node involvement in one zone [33]. 
Currently, adjuvant treatment decisions are based on the postoperative, pathological lymph 
node status with no regard to the individual nodal tumor burden. Based on the observed 
differences in survival depending on involved lymph node subgroups, future therapy trials 
should aim at analyzing a possible impact of adjuvant and neoadjuvant treatment regimens 
based on more detailed patient stratification depending on single lymph node stations. New 
therapeutic strategies like targeted therapy and immunotherapy might increase disease 
control for patients with locoregional disease and hilar lymph node involvement [37, 38]. 
Taken together, the involvement of the different lymph node positions could be of prognostic 
relevance for the evaluation of the tumor immune response and development of effective 
new therapeutic strategies. 
 
 
5. Contribution of the PhD candidate 
 
Concerning the publication “Comprehensive clinical profiling of the Gauting locoregional lung 
adenocarcinoma donors”, the PhD candidate designed the project together with her 
supervisor Dr. Georgios Stathopoulos. The PhD candidate acquired the clinical data from 
medical charts, follow-up visits, and phone calls. Statistical analyses were conducted by the 
PhD candidate together with her supervisor. Moreover, the PhD candidate wrote the first 
version of the manuscript. 
 
Regarding the publication “Prognostic relevance of regional lymph-node distribution in 
patients with N1-positive non-small cell lung cancer”, the PhD candidate collected and 







   
 
 
PUBLICATION   I 
 
 
Comprehensive clinical profiling of the Gauting locoregional lung adenocarcinoma 
donors 
 
Klotz LV, Courty Y, Lindner M, Petit-Courty A, Stowasser A, Koch I, Eichhorn ME, Lilis I, 
Morresi-Hauf A, Arendt KAM, Pepe M, Giopanou I, Ntaliarda G, Behrend SJ, Oplopoiou M, 
Gissot V, Guyetant S, Marchand-Adam S, Behr J, Kaiser JC, Hatz RA, Lamort AS, 





Cancer Med. 2019 Apr;8(4):1486-1499. doi: 10.1002/cam4.2031. 
 










1486  |    Cancer Medicine. 2019;8:1486–1499.wileyonlinelibrary.com/journal/cam4
Received: 30 November 2018 | Revised: 24 January 2019 | Accepted: 27 January 2019
DOI: 10.1002/cam4.2031
O R I G I N A L  R E S E A R C H
Comprehensive clinical profiling of the Gauting locoregional lung 
adenocarcinoma donors
Laura V. Klotz1,2 |   Yves Courty3 |   Michael Lindner1,2 |   Agnès Petit-Courty3 |   
Anja Stowasser1 |   Ina Koch1 |   Martin E. Eichhorn1,4 |   Ioannis Lilis5 |   
Alicia Morresi-Hauf6 |   Kristina A.M. Arendt2 |   Mario Pepe2 |   Ioanna Giopanou5 |   
Giannoula Ntaliarda5 |   Sabine J. Behrend2 |   Maria Oplopoiou5 |   Valérie Gissot7 |   
Serge Guyetant3,8 |   Sylvain Marchand-Adam3,8 |   Jürgen Behr2,9 |    
Jan-Christian Kaiser10 |   Rudolf A. Hatz1 |   Anne-Sophie Lamort2 |    
Georgios T. Stathopoulos2,5
1Center for Thoracic Surgery Munich, Ludwig-Maximilians-University of Munich (LMU) and Asklepios Medical Center, Member of the German Center for 
Lung Research (DZL), Gauting, Bavaria, Germany
2Comprehensive Pneumology Center and Institute for Lung Biology and Disease, University Hospital, Ludwig-Maximilians University of Munich (LMU) 
and Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Munich, Bavaria, Germany
3French National Institute of Health and Medical Research (INSERM) Unit 1100, Faculty of Medicine, Research Center for Respiratory Diseases 
(CEPR), University F. Rabelais, Tours Cedex, Centre, France
4Department of Thoracic Surgery, Ruprecht-Karls-University of Heidelberg, Heidelberg, Baden-Württemberg, Germany
5Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Biomedical Sciences Research 
Center, Achaia, Greece
6Department of Pathology, Asklepios Medical Center, Gauting, Bavaria, Germany
7INSERM, Center for Clinical Investigation (CIC) Unit 1415, Regional University Hospital Center (CHRU) Tours, Bretonneau Hospital, Tours Cedex, 
Centre, France
8Regional University Hospital Center (CHRU) Tours, Department of Pathology and Tumor Biobank, Bretonneau Hospital, Tours Cedex, Centre, France
9Department of Pneumology, Asklepios Lung Clinic Gauting, Member of the German Center for Lung Research (DZL), Gauting, Bavaria, Germany
10Institute of Radiation Protection (ISS), Helmholtz Center Munich, Neuherberg, Bavaria, Germany
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Laura V. Klotz, Anne‐Sophie Lamort and Georgios T. Stathopoulos are equally contributing authors.
Correspondence
Georgios T. Stathopoulos, Comprehensive 
Pneumology Center, Munich, Germany.
Email: stathopoulos@helmholtz-muenchen.de
Abstract
A comprehensive characterization of lung adenocarcinoma (LADC) clinical features 
is currently missing. We prospectively evaluated Caucasian patients with early‐stage 
LADC. Patients with LADC diagnosed between 2011 and 2015 were prospectively 
assessed for lung resection with curative intent. Fifty clinical, pathologic, radiologic, 
and molecular variables were recorded. Patients were followed till death/study 
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1 |  INTRODUCTION
Lung adenocarcinoma (LADC) is the most frequent histo-
logic type of lung cancer.1,2 It constitutes the most deadly 
human cancer, causing 650 000 deaths per year worldwide,3,4 
while its incidence is increasing in active smokers, ex‐smok-
ers, and never‐smokers.5 Simultaneously, LADC is the most 
frequent lung cancer in never‐smokers, women, and young 
patients, rendering understanding and treating the disease 
imperative.5,6 LADC is mainly caused by smoking, radia-
tion, and other exposures.5,7 Although multiple approaches to 
prevention/early detection have been evaluated, only 15% of 
patients diagnosed with LADC are amenable to surgery, the 
only definitive cure.8 These patients are of tremendous im-
portance, since they donate tissues for research that has fos-
tered our understanding of the pathobiology of locoregional 
LADC and has enabled targeted therapies for patients with 
defined oncogenic driver mutations.9,10
Recent molecular evidence indicates LADC to be a distinct 
disease entity.11 However, the clinical gestalt of the disease has 
not been comprehensively characterized separately from other 
forms of lung cancer. Here we report the first results from the 
Gauting locoregional lung adenocarcinoma donors (GLAD) 
study, a prospective biobank of LADC tissues and clinical phe-
notypes. The wealth of clinical information provided includes 
multiple variables and prolonged follow‐up data, enabling the 
discovery of new associations reported here, as well as the fu-
ture establishment of genotype‐phenotype links.
2 |  MATERIAL AND METHODS
2.1 | Studies approval
GLAD was conducted in accord with the Helsinki 
Declaration, reported in accord to STROBE (https://www.
strobe-statement.org/index.php?xml:id=strobe-home), ap-
proved by the LMU Ethics Committee (623‐15), registered 
with the German Clinical Trials Register (http://www.drks.de/
drks_web/navigate.do?navigationId=trial.HTML&TRIAL_
ID=DRKS00012649), and written informed consent was ob-
tained from all patients (https://www.asklepios.com/gauting/
experten/experten/biobank/). The Tours study was conducted 
according to the Helsinki Declaration, was approved by the 
Ethics Committee of Région Centre (2015/051), and was reg-
istered with the French Ministry of Health (DC‐2008‐308). 
All patients gave written informed consent.
2.2 | GLAD study
All patients with histologic LADC diagnosis at Asklepios 
Medical Center between February 2011 and September 
2015 were prospectively evaluated for lung resection with 
curative intent. LADC was staged according to the current 
Seventh Edition of the International Association for the 
Study of Lung Cancer (IASLC) tumor–node–metastasis 
staging system (TNM7).2 Preoperative lung function was 
assessed according to current guidelines.12 The Absolute 
Funding information
This work was supported by institutional 
funds. The study sponsors had no role in 
study design, data collection, analysis, 
interpretation, writing, and submitting the 
paper for publication.
conclusion. The main findings were compared to a separate cohort from France. Of 
1943 patients evaluated, 366 were enrolled (18.8%; 181 female; 75 never‐smokers; 
28% of registered Bavarian cases over the study period). Smoking and obstruction 
were significantly more prevalent in Gauting Lung Adenocarcinoma Donors (GLAD) 
compared with adult Bavarians (P < 0.0001). Ever‐smoker tumors were preferentially 
localized to the upper lobes. We observed 120 relapses and 74 deaths over 704 cumu-
lative follow‐up years. Median overall and disease‐free survival were >7.5 and 
3.6 years, respectively. Patients aged <45 or >65 years, resected >60 days postdiag-
nosis, with abnormal FVC/DLCOVA, N2/N3 stage, or solid histology had significantly 
decreased survival estimates. These were fit into a weighted locoregional LADC 
death risk score that outperformed pTNM7 in predicting survival in the GLAD and in 
our second cohort. We define the clinical gestalt of locoregional LADC and provide a 
new clinical tool to predict survival, findings that may aid future management and 
research design.
K E Y W O R D S
LADC, lung adenocarcinoma, obstruction, smoking, survival
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and percentage predicted values for forced vital capacity 
(FVC), forced expiratory volume in 1 sec (FEV1), FEV1/
FVC ratio, lung diffusion capacity for carbon monox-
ide (DLCO), and DLCO corrected for alveolar ventilation 
(DLCO/VA) were recorded. Patients eligible and fit for sur-
gery were prospectively enrolled. Baseline data obtained 
at entry were: blinded patient identifier (ID), age and sex, 
body mass and length, date and mode of clinical and tis-
sue diagnosis, clinical TNM7 (cTNM7) stage including 
site and extent of metastatic disease, smoking start, stop, 
and intensity, and lung function results. Chronic obstruc-
tive pulmonary disease (COPD) was defined as smoking 
>30 pack‐years with compatible symptoms and FEV1/FVC 
<70% and was graded by the global initiative for chronic 
obstructive lung disease (GOLD) 2001 classification.13 
All patients were re‐evaluated at 30 days postsurgery, the 
benchmark of referral to oncology/radiotherapy (all stage 
III/IV patients received adjuvant therapy) or dismissal to 
out‐patient follow‐up according to current guidelines.14 
Data prospectively recorded included: date of surgery, 
time from diagnosis to treatment calculated from imag-
ing/tissue diagnosis (whichever occurred first) to resection 
date, blinded tissue ID, lobar tumor location, relapse/me-
tastasis date and site, histologic subtype, pathologic TNM7 
(pTNM7) stage, and oncogene testing results. Follow‐up 
data were retrospectively acquired from visits, medical 
charts, telephone consultations with treating physicians, 
and/or death certificate searches and included: adjuvant 
therapy, relapse/metastasis date, site, and extent, and death 
or last contact. Primary endpoint was overall survival (OS), 
calculated from surgery to death (event) or last contact 
(censored); secondary endpoint was disease‐free survival 
(DFS), calculated from surgery until recurrence (event) or 
last contact (censored); tertiary endpoints were associations 
between the variables obtained.
2.3 | Tours comparison cohort
All patients with tissue‐diagnosed LADC between January 
2006 and December 2011 were prospectively evaluated for 
curative resection, staged according to TNM7,2 preopera-
tively tested for lung function, prospectively enrolled if eli-
gible, and fit for surgery. Data obtained and endpoints were 
identical to GLAD, except from histologic subtype, extent of 
metastatic disease, and oncogene test results.
2.4 | Histology and genotyping
LADC subtypes of GLAD were determined by our pathology 
expert (AMH) according to IASLC guidelines.1,2
2.5 | Statistics
Minimal study size (nMIN) was determined by power analy-
ses (http://www.gpower.hhu.de/en.html) employing Fisher's 
exact test, proportion inequalities in two independent groups, 
α error=0.05, 80% power, and 1:1 allocation ratio. nMIN = 314 
was required to detect the difference between 0% and 5% and 
n
MIN = 348 between 30% and 45%. We targeted recruitment 
to n = 350 and achieved n = 366 in September 2015. Data 
distribution was tested using Kolmogorov‐Smirnov test and 
summaries are given as frequencies or point estimates (mean 
or median) with descriptors of dispersion (standard deviation, 
SD or interquartile range, IQR or 95% confidence interval, 
95%CI), as appropriate and indicated. Survival was analyzed 
by Kaplan‐Meier estimates and Cox proportional hazard 
models using Waldman backward elimination. Log rank tests 
were used for comparisons. Associations between variables 
were examined using Fisher's exact or χ2 tests, Student's 
t‐ or Mann‐Whitney U‐tests, one‐way analysis of variance 
(ANOVA) with Bonferroni posttests or Kruskal‐Wallis 
ANOVA with Dunn's posttests, Pearson's or Spearman's cor-
relations, and linear regression, depending on input and target 
variable nature and distribution, as appropriate and as indi-
cated. Probabilities (P) < 0.05 were considered significant. 
Least absolute shrinkage and selection operator (LASSO) 
regression analysis was carried out using the GLMNET 
package on R*, where the number of regression coefficients 
shrunk according to a penalization factor λ (https://www.r-
project.org/) and their point estimates were determined with 
cross‐validation using 244 samples with complete records. 
Unsupervised clustering of 362 GLAD patients was done 
using ConsensusCluster;15 settings were K = 2‐6, subsample 
size = 300, and fraction = 0.8, K‐means algorithm with aver-
age linkages, hierarchical consensus, and Euclidean distance 
metric, and center principal component analysis normalization 
with fraction = 0.85 and eigenvalue weight = 0.25. Receiver‐
operator curves (ROC) were used to identify variables defin-
ing patient clusters. Analyses were done on the Statistical 
Package for the Social Sciences v24.0 (IBM, Armonk, NY) 
and Prism v5.0 (GraphPad, San Diego, CA).
F I G U R E  1  The Gauting locoregional lung adenocarcinoma donors (GLAD) study overview and main results at the mid‐2016 census. (A) 
Venn diagram of current smoking and COPD prevalence, and LADC incidence over the GLAD study period in Bavaria. Data were obtained from 
the present study, from the Bavaria cancer registry, and from references 16‐18. (B) Study flowchart. (C) Study timeline. (D) Cumulative relapse 
events observed by site at the 30‐day postresection and long‐term follow‐up benchmarks. Shown are number of observations (n) and χ2 test 
probability (P). (E) Kaplan‐Meier plots and estimates of overall and disease‐free survival with patient numbers at risk, events observed, and patients 
censored (graph) and actual (excluding censored observations) percentage of patients surviving at 1, 2, 3, 5, and 7 years postresection (table)
16
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3 |  RESULTS
3.1 | The Gauting locoregional lung 
adenocarcinoma donors (GLAD)
During the period from February 2011 to September 2015, 
1943 patients with LADC were prospectively assessed in the 
Asklepios Medical Center, Gauting, Germany. Among them, 
455 were eligible and fit for curative surgery, and 366 were 
enrolled (89 patients were excluded due to cTNM7 N3 disease 
or unwillingness to provide informed consent). They represent 
~28% of registered Bavarian locoregional LADC cases during 
the study period (21 588 lung cancer cases, corresponding to 
8635 LADC cases at expected 40%, and to 1295 resectable 
LADC cases at expected 15%; http://www.krebsregister-bay-
ern.de/index_e.html) summarized in Figure 1A.16-18 During 
the same period, another 1577 patients with LADC were not 
eligible or fit for lung resection, rendering 23% of patients 
screened resectable with intention to treat, and resulting in 
19% recruitment rate into GLAD (Figure 1B and C). Of the 
366 patients resected, 41 had oligometastatic disease detected 
prior to surgery, seven were incompletely resected, and in 20 a 
malignant pleural disease was identified intraoperatively. Out 
of the 305 patients that were tumor‐free after surgery, 301 re-
mained tumor‐free at the 30‐day postoperative census (82.2%), 
and 181 (49.5%) at the mid‐2016 census (Figure 1D). At this 
time, 8453 cumulative follow‐up months (median[interquartile 
range, IQR] 18 [7‐33] months/patient) had been delivered, and 
120 relapses and 74 deaths were observed. Median(95% con-
fidence interval, CI) overall survival (OS) was not reached 
(>7.5 years), disease‐free survival (DFS) was 3.64 (2.76‐5.88) 
years, and 5‐year OS and DFS rates were 62% and 39%, respec-
tively (Figure 1E). GLAD will be re‐censored mid‐biannually; 
hence survival data are expected to evolve. A color‐coded phe-
nome plot of all information available at the mid‐2016 census 
is shown in Figure 2 and Table S1, while a heat map of all the 
associations observed (discussed below) is given in Figure 3. 
The major findings from GLAD classified according to clini-
cal variables are presented below.
3.2 | Age
In GLAD, median(IQR) age was 67 (59‐72) years, including 
11 (3%) and 195 (53%) patients younger than 45 and older 
than 65 years, respectively; those had markedly decreased 
overall survival (OS) and disease‐free survival (DFS) com-
pared with 160 (44%) patients aged between 45 and 65 years 
(Figure 4A and B). Age was positively associated with cu-
mulative smoke exposure and lepidic/papillary histology. On 
the contrary, it was negatively linked with current smoking, 
body length, FVC and FEV1, and time to surgery (Figure 3). 
In addition, more death and relapse events were observed in 
patients of extreme age (<45 or >65 years) (Figure S1A). 
Linear regression‐calculated lung function decline rates with 
age were similar to the Framingham study,19 and lung func-
tion test results were tightly correlated with body metric in-
dices, validating GLAD lung function data (Figure S1B‐D). 
Interestingly, patients with affected resection margins and 
perioperative pleural relapse were significantly younger 
(Figure S1A).
3.3 | Sex
Surprisingly, 181 patients (49.5%) of GLAD were female, 
reflecting increasing local and worldwide female smoking 
trends.6,20 Female sex was positively associated with percent 
predicted FVC and FEV1 values and FEV1/FVC ratio, and 
negatively linked with smoking rate and intensity, body met-
ric indices, absolute FVC and FEV1 and percent predicted 
DLCO/VA, COPD frequency, solid histologic subtype, and ad-
renal relapse (Figure S2). However, sex did not significantly 
impact survival (Figure 4B). These results suggested that lo-
coregional LADC in Caucasian women has distinct features 
as proposed elsewhere.6 However, these do not profoundly 
alter the biologic course of the disease, in accord with pub-
lished results from Norway.20
3.4 | Smoking
The GLAD study included 75 never (20.5%), 130 former 
(35.5%), and 161 current (44.0%) smokers. Alarmingly, 
active smokers were younger (Figure 4C). Smoking absti-
nence of ex‐smokers was median(IQR) = 10(5‐25) years. 
Importantly, more than 50% of patients were never/ex‐
smokers (Figure 1A). GLAD smoking rates were dispropor-
tional to a Norwegian cohort of 54 never (7.8%), 255 former 
(36.8%), and 383 current (55.3%) smokers (P < 0.0001 
F I G U R E  2  GLAD phenome plot. Color‐coded pivot table of all data obtained from GLAD sorted sequentially by cTNM7 stage, histologic 
subtype, sex, and smoking status. Columns represent individual patients and rows variables recorded at study entry, postsurgery census, and 
longitudinal follow‐up. The raw data table is provided as Table S2. n, sample size; ID, identifier; FVC, forced vital capacity; FEV1, forced 
expiratory volume in 1 seconds; DLCO, uncorrected lung diffusion capacity for carbon monoxide; VA, alveolar ventilation; COPD, chronic 
obstructive pulmonary disease; GOLD, global initiative for chronic obstructive lung disease; TNM, tumor‐node‐metastasis staging system; 
c, clinical; p, pathologic; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL left lower lobe; 
EGFR, epidermal growth factor receptor; KRAS, V‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog; BRAF, v‐Raf murine sarcoma viral 
oncogene homolog B; EML4, echinoderm microtubule associated protein like 4; ALK, anaplastic lymphoma kinase; LADERS, locoregional lung 
adenocarcinoma death risk score; nd, not determined
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compared with GLAD, χ2 test),20 but proportional to a 
French cohort from Tours that included 39 never (14.3%), 
102 former (37.4%), 124 current (45.4%), and 8 indetermi-
nate (2.9%) smokers (P = 0.1114 compared with GLAD, χ2 
test).21 Hence the Tours cohort was identified as an optimal 
comparison set (Figure S3, Table S2). Expectedly, current 
smoking was significantly more frequent (P = 0.0044, χ2 
test) in GLAD (44%) compared with current Bavarian rates 
(24.2%) (Figure 4D).17 Median(IQR) pack‐years smoked 
were 40 (9‐60), and smoking exposure correlated negatively 
with lung function, especially DLCO/VA (Figure S4A‐C). 
Moreover, in accord with published results,22 active smok-
ing was associated with solid, and never smoking with acinar 
histology (Figure S4D). Interestingly, smoking was nega-
tively associated with N stage, postoperative pleural relapse, 
as well as bone metastasis (Figure S4D).9 However, smoking 
did not affect survival (Figure S4E and F). Collectively the 
data indicate that smoking is intimately linked with LADC 
and suggest that active smoking continuously drives the 
disease in the lungs, likely via tumor‐promoting effects of 
nicotine.23
3.5 | Obstruction and COPD
When GLAD were classified according to original GOLD 
criteria,13 patients had stage 0 (62.8%), 50 patients stage I 
(13.7%), 75 patients stage II (20.5%), 6 patients stage III 
(1.6%), and 5 patients indeterminate (1.4%) COPD status 
(Figure 2). Smoking was intimately linked with GOLD 
COPD stage (P < 0.0001, Fisher's exact test) and COPD 
was significantly more prevalent in GLAD compared with 
current Bavarian rates (P < 0.0001, Fisher's exact test; 




GLAD and Tours cohorts (Figure 1A, Figure S3A),24 un-
derpinning the causative role of smoking in both COPD and 
LADC.25 Lung function tests were concordant to GOLD 
COPD definition (Figure S5A). COPD was positively as-
sociated with affected resection margins and perioperative 
pleuropulmonary relapse likely attributable to adverse ef-
fects of distorted lung structure on surgical outcome, and 
correlated negatively with FVC and DLCO/VA (Figure S5B). 
However, COPD did not impact survival (Figure S5C and 
D). Of all lung function variables, only abnormal percent-
age predicted FVC and DLCO/VA negatively impacted sur-
vival (Figure S5E and F). Collectively, the data indicate 
that COPD and LADC show significant overlap, suggest-
ing a common pathogenesis, in line with the literature.25 
Moreover, the percentage predicted FVC and DLCO/VA, but 
not other spirometry indices or a diagnosis of COPD, can 
predict survival.
3.6 | cTNM7 staging
All patients were staged according to cTNM7 to guide man-
agement.2,14 We included history, physical exam, and chest‐to‐
adrenal computed tomography in all. For stage III patients, an 
invasive bronchoscopy with mediastinal lymph node sampling, 
mediastinoscopy, and/or 18fluoro‐deoxyglucose positron emis-
sion tomography were also performed. Analysis of T, N, and 
cTNM7 stage showed a significant impact on survival (Figure 
S6) and validated GLAD against the reference IASLC study.2
3.7 | Surgery
Time from imaging/tissue diagnosis to surgery was 
median(IQR) = 6 (0‐25) days. Resection within 60 days was 
achieved in 337 patients (92%), while 29 (8%) had resec-
tions performed >60 days after diagnosis. Out of 366 GLAD 
patients, 58 had preexisting oligometastatic, N3 disease, or 
pleural dissemination newly identified at surgery, leaving 
308 for resection with intent‐to‐treat. Complete resection 
was achieved in 301 of these patients (97.7%; P = 0.8639, 
Fisher's exact test). Importantly, time to surgery significantly 
affected overall and disease‐free survival (Figure 4F).
3.8 | Tumor location
The lobe of origin of GLAD tumors was definitively deter-
mined during surgery in 296 patients, while tumors involving 
multiple lobes, central airways, and/or mediastinal structures 
rendered this impossible in 70 patients. We identified a strik-
ing upper lobe predominance in both GLAD and Tours co-
horts, which was disproportional to published lobe ventilation 
or perfusion patterns, and was reminiscent of lobar ventilation/
perfusion ratios (Figure 4G‐I).26,27 Strikingly, RUL LADCs 
predominated in smokers of both cohorts, and patients with 
RUL LADC displayed higher FVC, FEV1, and N stage, but 
similar survival, compared with all other patients (Figure S7).
3.9 | Histology
After the pathologic review of multiple tumor sections 
and sites (AMH), GLAD were classified into 16 lepidic 
(4.4%), 141 acinar (38.5%), 70 papillary (19.1%), 126 solid 
(34.4%), 2 fetal (0.5%), 2 adenosquamous (0.5%), 4 mi-
cropapillary (1.1%), and 5 indeterminate (1.4%) histologic 
subtypes. Papillary histology was more frequent compared 
with a published reference cohort that comprised 41 le-
pidic (8.2%), 207 acinar (41.4%), 23 papillary (4.6%), 183 
solid (36.6%), 33 micropapillary (6.6%), and 13 indeter-
minate (2.6%) locoregional LADC (P < 0.0001, χ2 test).22 
Encouragingly, indeterminate tumor rate was low in both 
studies, indicating the reproducibility of the IASLC classi-
fication.1,2,23 In accord with the above‐referenced study,22 
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F I G U R E  3  GLAD association heatmap. Color‐coded pivot table of all associations observed in the GLAD cohort. Colors represent the 
direction and probability of observed associations and letters the statistical method employed to detect them. n, sample size; FVC, forced vital 
capacity; FEV1, forced expiratory volume in 1 seconds; DLCO, uncorrected lung diffusion capacity for carbon monoxide; VA, alveolar ventilation; 
COPD, chronic obstructive pulmonary disease; GOLD, global initiative for chronic obstructive lung disease; TNM, tumor‐node‐metastasis staging 
system; c, clinical; p, pathologic; EGFR, epidermal growth factor receptor; KRAS, V‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog; BRAF, 
v‐Raf murine sarcoma viral oncogene homolog B; EML4, echinoderm microtubule associated protein like 4; ALK, anaplastic lymphoma kinase
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lepidic‐predominant tumors in LADC was more frequent in 
never‐smokers and displayed lower overall TNM descrip-
tors, decreased metastatic propensity, and prolonged over-
all survival, as opposed to solid‐predominant LADC that 
displayed aggressive features and poor survival (Figure 
S8), further validating GLAD.
3.10 | Patterns of relapse
Over 704 cumulative follow‐up years, 190 relapse events 
were identified in 120 patients (Figure 1D). In addition 
to the associations described above, patients with higher 
cTNM7 descriptors had higher relapse rates, both at the 
F I G U R E  4  Incidence of different clinical parameters on LADC development in GLAD. (A, B, F) Kaplan‐Meier disease‐free and overall 
survival plots and overall log‐rank test probability values (P) of the GLAD. (A) Stratified by age (n = 11, 160, and 195, respectively, for age groups 
<45, 45‐65, and >65 years). (B) Stratified by sex (n = 181 and 185, respectively, for women and men). (C) Smoking exposure stratified by age. 
Shown are patient numbers (n), raw data points (dots), mean (columns), SD (bars), and Kruskal‐Wallis test probability (P). * and ***: P < 0.05 
and P < 0.001, respectively, for the indicated comparisons by Dunn's posttests. (D) Crosstabulations of current smoking and COPD prevalence 
in GLAD and in Bavaria. Data were obtained from the present study and from references 22 and 24. COPD was staged according to the GOLD 
classification (28). Shown are percentages and Fisher's exact probability (P). (E) Crosstabulation of smoking status and GOLD COPD stage in 
GLAD. Shown are patient numbers (n) and χ2 probability (P). (F) Stratified by timely (n = 337) or delayed (n = 29) resection and by complete 
(n = 310) or incomplete (n = 56) resection. (G‐H) LADC location by lung lobe determined at surgery (G) in the GLAD derivation cohort, (H) in 
a smoking‐optimal comparison cohort from Tours, France, (I) in COSMIC database (https://cancer.sanger.ac.uk/cosmic). Shown are schematic 
representations of the lungs with their lobes (RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, 
left lower lobe) and the number (n) and percentage of tumors observed. Color indicates frequency. (J) Crosstabulations of relapse events in the 
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30‐day postsurgery and at mid‐2016 benchmarks (Figures 4J 
and 5). Relapse timing and site did not significantly impact 
OS; however, pleural or multi‐site relapse (5/20 patients 
with multiple relapses also had pleural relapse) adversely 
impacted DFS indicating that pleural relapse occurs earlier 
than others (Figure S9).
F I G U R E  5  Development of the locoregional lung adenocarcinoma death risk score (LADERS) from the GLAD derivation cohort. (A) 
Results of least absolute shrinkage and selection operator (LASSO) regression. Shown are regression coefficients for overall (OS) and disease‐free 
(DFS) survival and color‐coded direction of impact on survival. (B) Results of Cox regression showing proportional hazards survival plots for 
the six independent predictors of survival of GLAD, including sample sizes (n) and probability values (P). (C) Schematic representation of the 
components and relative weight of the variables that comprise LADERS compared with the TNM staging system, including χ2 probability value 
(P). FVC, forced vital capacity; FEV1, forced expiratory volume in 1 seconds; DLCO, uncorrected lung diffusion capacity for carbon monoxide; VA, 
alveolar ventilation; GOLD, global initiative for chronic obstructive lung disease; COPD, chronic obstructive pulmonary disease; TNM, tumor‐
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F I G U R E  6  Performance of LADERS and pTNM7 as prognosticators in two locoregional lung adenocarcinoma patient cohorts. (A, B) 
Results from the GLAD derivation cohort. (C, D) Results from the Tours validation cohort. (A, C) Shown are LADERS distribution pie charts and 
patient numbers (n), LADERS groupings employed, and mean (because median was not reached for low LADERS scores) Kaplan‐Meier survival 
and Cox proportional hazards estimates with 95% confidence intervals (95%CI) of LADERS groupings. (B, D) Shown are Kaplan‐Meier and 
Cox proportional hazards survival plots and overall log‐rank test and Cox probability values (P) for LADERS and pTNM7 groupings, showing 
that LADERS more accurately predicted death events. TNM, tumor‐node‐metastasis staging system; p, pathologic; LADERS, locoregional lung 
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3.11 | Survival
We next assessed the impact of each variable on OS and DFS. 
In a first step, Kaplan‐Meier analyses using OS and DFS as 
target and single variables as inputs (continuous numerical 
variables were dichotomized at abnormal cutoffs) showed 
that patients with age outlying 45‐65 years, abnormal per-
centage predicted FVC and DLCO/VA, high T, N, and cTNM7 
descriptors, delayed and incomplete resection, solid histo-
logic subtype, and pleural relapse; had decreased OS and/or 
DFS (Figures 4A and 4F, Figures S5E and F, S6, S8C and D, 
S9B). All variables were entered into a second line least ab-
solute shrinkage and selection operator (LASSO) regression 
analysis that identified age, body mass, percentage predicted 
FVC, FEV1/FVC ratio, percentage predicted DLCO, GOLD 
COPD stage, T, N, and cTNM7 stage, time to surgery, right 
lower lobe origin, and histologic subtype as determinants of 
OS and/or DFS (Figure 5A). In a final step, all variables that 
emerged both from Kaplan‐Meier and LASSO analyses were 
entered into Cox regression using backward Waldman elimi-
nation, which identified age outlying 45‐65 years, abnormal 
percentage predicted FVC and DLCO/VA, N2/3 disease, de-
layed resection, and solid histology as independent predictors 
of OS of GLAD (Figure 5B).
3.12 | The locoregional lung 
adenocarcinoma death risk score (LADERS)
We next built a model to predict OS at the 30‐day postre-
section benchmark, using the six variables that withstood 
Kaplan‐Meier, LASSO, and Cox regression testing using 
OS as the target. LADERS employs Cox proportional hazard 
points and was tailored for easy clinical use without extra 
imaging/procedures (Figures 5C and 6A and B, Table 1). 
LADERS displayed only 25% correlation with pTNM7 
and was intimately linked with death events, while pTNM7 
showed tight linkage with relapse events (Figure S10A and 
B). LADERS outperformed pTNM7 in predicting OS of 
GLAD in Kaplan‐Meier and Cox regression analyses, while 
pTNM7 performed better in predicting DFS (Figure S10C; 
Table 2). LADERS also outperformed pTNM7 in predicting 
OS in the Tours cohort (Figure 6C and D).
4 |  DISCUSSION
Here we present GLAD, a prospectively evolving biobank of 
phenotypes and tumor/normal paired tissues of patients with 
locoregional LADC. The longitudinal follow‐up of the co-
hort suggests that locoregional LADC is currently a chronic 
lung disease with median survival >7.5 years. We corrobo-
rate pertinent findings of previous studies, such as the high 
frequency of these tumors in never/ex‐smokers and women 
and the significant overlap of LADC with COPD, the upper 
lobe predominance of these tumors that appears to be dexter-
ous in smokers, as well as the value of current staging and 
histologic typing systems in management and prognosis.1,2,22 
Using detailed phenotyping and prolonged follow‐up, we 
discovered previously ill‐defined and undefined clinical as-
sociations, such as the adverse effects of extreme age, poor 
lung function, and delayed resection on survival, as well as 
the early nature of pleural and the latency of pulmonary re-
lapse. Most of our findings are corroborated in a separate pa-
tient cohort from France. Most importantly, we combined this 
wealth of clinical information to produce LADERS, a clinical 
score that accurately predicts survival in both cohorts.
Variable
Hazard ratio (95% 
confidence interval) Probability Hazard points
Age <45 or >65 years 4.12 (2.35‐7.23) 0.0000008 3
FVCa <80% predicted 2.13 (1.25‐3.63) 0.0054374 1
DLCO/VA
b <70% predicted 2.62 (1.60‐4.29) 0.0001292 2
N2c 3.56 (2.20‐5.76) 0.0000002 2.5
N3c 8.65 (1.10‐68.21) 0.0406576 7.5
Time to surgery >60 daysd 4.04 (2.07‐7.88) 0.0000408 3
Solid histologic subtypee 2.09 (1.27‐3.43) 0.0035422 1
LADERSf 0‐20
aFVC, forced vital capacity. Compared with FVC ≥80% predicted. When FVC not available, GOLD COPD 
≥stage II was used in the Tours cohort. 
bDLCO/VA, Lung diffusion capacity for carbon monoxide corrected for alveolar ventilation. Compared with 
DLCO/VA ≥70% predicted. When DLCO/VA not available, current smoking was used in the Tours cohort. 
cN, cTNM7 nodal status descriptors. Compared with pooled patients with N0 and N1. 
dCompared with patients operated within 60 days from diagnosis. 
eCompared with all other histologic subtypes combined, including lepidic, acinar, papillary, micropapillary, 
adenosquamous, fetal, and non‐specified. 
fRounded to the lower integer when decimal. 
T A B L E  1  Independent predictors of 
survival identified by proportional hazards 
Cox regression analysis and locoregional 
lung adenocarcinoma death risk score 
(LADERS)
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In accord with only one previous report,28 young GLAD 
patients developed more aggressive LADC, possibly attrib-
utable to germline tumor suppressor loss, a hypothesis that 
can be directly tested in GLAD tissues. On the other hand, 
extremely old patients appeared to have a worse surgical 
prognosis associated with reduced lung and overall function. 
Active smokers had low N stage and relapse rates, findings 
possibly related with the young age and increased surveil-
lance of active smokers in our cohort.
For the first time, we report how important time to surgery 
is for incipient survival, underscoring the aggressiveness of 
the disease and the urgency of surgery. We also define a pre-
viously reported spatial pattern of LADC development in the 
upper lobes.29 Although the clinical importance of this finding 
is unclear, it is likely the result of increased local conversion 
of inhaled precarcinogens to active carcinogens in the upper 
lobes of smokers. Of special note, we identify distinct temporal 
trends in organ‐specific relapse of early‐stage LADC, similar 
to biphasic metastatic patterns of other tumor types like breast 
cancer.30 Importantly, we provide clinicians with LADERS, an 
easy‐to‐use and accurate clinical tool to predict survival.
In conclusion, the first results from a prospective cohort of 
patients with locoregional LADC corroborate the impact of 
current staging and histologic subtyping systems and identify 
important effects of age, lung function, and time to resection 
on survival. A clinical tool to assess survival is also provided. 
Importantly, future combination of clinical information with 
tissue profiling is anticipated to unveil novel tumor genome‐
phenome links and unprecedented mechanistic insights into 
evolution of carcinogenesis in the respiratory tract.
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Figure S5. Chronic obstructive pulmonary disease (COPD) in the GLAD cohort.  
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Figure S9. Patterns of relapse of GLAD.. 
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Figure S10. Comparison of the lung adenocarcinoma death risk score (LADERS) to TNM 
systems and their impact on disease-free survival.  
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SUPPLEMENTARY FIGURE LEGENDS 
 
Figure S1. Impact of age on GLAD. (A) Crosstabulations of GLAD by age groupings. Shown are 
patient numbers (n), color coded frequencies by age grouping, and Fischer’s exact probabilities (P). 
(B-D) Correlations of age and body metric indices with lung function tests (n = 366). Shown are raw 
data points (dots), linear regression lines and coefficients, and squared Pearson’s correlation 
coefficients (R2) and probabilities (P). n, sample size; DLCO, uncorrected lung diffusion capacity for 
carbon monoxide; VA, alveolar ventilation; EML4, echinoderm microtubule associated protein like 4; 
ALK, anaplastic lymphoma kinase; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 sec. 
 
Figure S2. Associations with sex in the GLAD cohort. (A) Crosstabulations of GLAD by sex. Shown are 
patient numbers (n), color coded frequencies by sex, and Fischer’s exact probabilities (P). (B) 
Smoking exposure, body metric indices, and lung function parameters stratified by sex. Shown are 
patient numbers (n), raw data points (dots), mean (columns), SD (bars), and Mann Whitney test 
probabilities (P).  
 
Figure S3. The Tours locoregional lung adenocarcinoma donors cohort. (A) Venn diagram of current 
smoking COPD prevalence, and LADC incidence over the Tours study. (B) Phenome plot of the Tours 
cohort (raw data available in Table S2). Color-coded pivot table of all data obtained sorted 
sequentially by cTNM7 stage, tumor grade, sex, and smoking status. Columns represent individual 
patients and rows variables recorded. n, sample size; ID, identifier; FVC, forced vital capacity; FEV1, 
forced expiratory volume in 1 sec; DLCO, uncorrected lung diffusion capacity for carbon monoxide; 
VA, alveolar ventilation; COPD, chronic obstructive pulmonary disease;  GOLD, global initiative for 
chronic obstructive lung disease; TNM, tumor-node-metastasis staging system; c, clinical; p, 
pathologic; EGFR, epidermal growth factor receptor; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog; LADERS, locoregional lung adenocarcinoma death risk score; nd, not 
determined.  
 
Figure S4. Smoking status, exposure, and effects in the GLAD cohort. (A) Age, body mass, and lung 
function parameters stratified by smoking status. Shown are patient numbers (n), raw data points 
(dots), mean (columns), SD (bars), and Kruskal-Wallis test probabilities (P). ns, **, and ***: P > 0.05, 
P < 0.01, and P < 0.001, respectively, for the indicated comparisons by Dunn’s post-tests. (B, C) 
Correlations of smoking exposure with lung function tests (n = 366). Shown are raw data points 
(dots), linear regression lines and coefficients, and squared Pearson’s correlation coefficients (R2) 
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and probabilities (P). (D) Crosstabulations of GLAD by smoking status. Shown are patient numbers 
(n), color coded frequencies by smoking status, and Fischer’s exact probabilities (P). (E, F) Kaplan-
Meier disease-free and overall survival plots and overall log-rank test probability values (P) of the 
GLAD stratified by smoking status (n = 75, 130, and 161, respectively, for never, former, and current 
smokers). n, sample size; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 sec; DLCO, 
uncorrected lung diffusion capacity for carbon monoxide; VA, alveolar ventilation. 
 
Figure S5. Chronic obstructive pulmonary disease (COPD) in the GLAD cohort. (A) Age and lung 
function parameters stratified by COPD stage (n = 361 due to missing data in five patients) as 
defined by the global initiative for chronic obstructive lung disease 2001 criteria 18. Shown are 
patient numbers (n). raw data points (dots), mean (columns), SD (bars), and Kruskal-Wallis test 
probabilities (P). ns, *, **, and ***: P > 0.05, P < 0.05, P < 0.01, and P < 0.001, respectively, for the 
indicated comparisons by Dunn’s post-tests. (B) Crosstabulations of GLAD by GOLD COPD stage. 
Shown are patient numbers (n), color coded frequencies by age grouping, and χ2 probabilities (P). (C, 
D) Kaplan-Meier disease-free and overall survival plots and overall log-rank test probability values 
(P) of the GLAD stratified by GOLD COPD stage (n = 229, 51, 75, and 6, respectively, for GOLD COPD 
stages 0, I, II, and III). (E, F) Kaplan-Meier overall survival plots and log-rank test probability values (P) 
of the GLAD stratified by normal or abnormal forced vital capacity (FVC) and  lung diffusion capacity 
for carbon monoxide corrected for alveolar ventilation (DLCO/VA) (FVC: n = 296 and 70, respectively, 
for values ≥ 80% and < 80%; DLCO/VA: n = 239 and 127, respectively, for values ≥ 70% and < 70%). n, 
sample size; FEV1, forced expiratory volume in 1 sec; DLCO, uncorrected lung diffusion capacity for 
carbon monoxide. 
 
Figure S6. Validation of GLAD cTNM7 staging. Kaplan-Meier overall (A, C, E) and disease-free (B, D, 
F) survival plots and overall log-rank test probability values (P) of the GLAD stratified by T (A, B), N (C, 
D), and cTNM7 (E, F) stage. n, sample size; TNM, tumor-node-metastasis staging system; c, clinical. 
 
Figure S7. Tumor location in the GLAD and Tours cohorts. (A) Crosstabulation of LADC location by 
lung lobe in the GLAD and Tours cohorts with lobar ventilation patterns determined by inhaled 
particle deposition and lobar perfusion patterns assessed via injected radioisotope distribution. 
Shown are number (n) of LADC observed, percentage of inhaled or injected particle distribution, 
overall χ2 probability (P) value, χ2 probability (P) values for comparison of each study to GLAD and 
Tours cohorts, and overall Cohen’s κ coefficient of agreement. Color indicates frequency. (B, C) LADC 
location by lung lobe determined at surgery in the GLAD derivation cohort and a smoking-optimal 
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comparison cohort from Tours, France that is presented in detail in Supplementary Table 2 and 
Figure 3. Shown are schematic representations and crosstabulations of the lungs with their five lobes 
(RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left 
lower lobe) and the number (n) and percentage of tumors observed in never, former, and current 
smokers, and Fischer’s exact (B) or χ2 (C) probabilities (P). Color indicates frequency. (D, E) Selected 
lung function parameters stratified by lobar tumor location in the GLAD cohort. Shown are patient 
numbers (n), raw data points (dots), mean (columns), SD (bars), and Student’s t test probabilities (P). 
(F) Crosstabulation of tumor location by N stage in GLAD. Shown are patient numbers (n), color 
coded frequencies by age grouping, and Fischer’s exact probability (P). (G) Kaplan-Meier disease-free 
and overall survival plots and log-rank test probability values (P) of GLAD patients stratified by tumor 
location in the right upper (n = 104) or any other (n = 29) lung lobe. n, sample size; LADC, lung 
adenocarcinoma; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 sec. 
 
Figure S8. Impact of histologic subtype on outcomes in the GLAD cohort. (A) Crosstabulations of 
histologic subtype by stage, relapse, and death related variables. Shown are patient numbers (n), 
color coded frequencies by histologic subtype, and Fischer’s exact probabilities (P). (B) Age stratified 
by histologic subtype. Shown are patient numbers (n), raw data points (dots), mean (columns), SD 
(bars), and Kruskal-Wallis test probability (P). *: P < 0.05 for comparison to other histologic subtype 
control (c) by Dunn’s post-tests. (C) Kaplan-Meier disease-free and overall survival plots and overall 
log-rank test probability values (P) of GLAD patients stratified by distinct histologic subtypes (n = 13, 
16, 141, 70, and 126, respectively, for other, lepidic, acinar, papillary, and solid subtypes). (D) 
Kaplan-Meier overall survival plot and log-rank test probability value (P) of GLAD patients classified 
into solid (n = 126) and other non-solid (n = 240) histologic subtypes. n, sample size; TNM, tumor-
node-metastasis staging system; c, clinical; p, pathologic. 
 
Figure S9. Patterns of relapse of GLAD. (A) Kaplan-Meier overall survival plot and overall log-rank 
test probabilities inclusive (P All groups) and non-inclusive (P Relapsed only) of patients without relapse of 
GLAD patients stratified by timing of relapse: no relapse (n = 201), early relapse (prior to the 30-day 
post-resection census; n = 45), late relapse (thereafter; n = 100), or both (n = 20). (B) Kaplan-Meier 
disease-free and overall survival plots and overall and pairwise (table insert) log-rank test 
probabilities inclusive (P All groups) and non-inclusive (P Relapsed only)  of patients without relapse of GLAD 
patients stratified by site of relapse: no relapse (n = 201), pulmonary relapse (n = 102), pleural 
relapse (n = 23), other extrathoracic relapse (n = 20), or multiple relapse sites (n = 20; five had also 
pleural relapse). n, sample size; TNM, tumor-node-metastasis staging system; c, clinical. 
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Figure S10. Comparison of the lung adenocarcinoma death risk score (LADERS) to TNM systems 
and their impact on disease-free survival. (A) Correlations of LADERS with cTNM7 (blue) and pTNM7 
(red; n = 366 for both). Shown are raw data points (dots), linear regression lines with 95% confidence 
intervals, and squared Pearson’s correlation coefficients (R2) and probabilities (P). (B) χ2 probability 
(P) values for crosstabulations of cTNM7, pTNM7, and LADERS with observed relapses and deaths in 
the GLAD (shown in B) show pTNM7 to be closest linked with relapse, but LADERS with death events. 
(C) Kaplan-Meier (top) and Cox proportional hazards (bottom) disease-free survival plots and overall 
log-rank test and Cox probability values (P) for LADERS and pTNM7 groupings confirm the closer 
linkage of pTNM7 to relapse events. n, disease; TNM, tumor-node-metastasis staging system; c, 
clinical; p, pathologic. 
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A B S T R A C T
Objective: Lymph node (LN) metastases predict survival in patients with non-small cell lung cancer (NSCLC)
treated with curative surgery. Nevertheless, prognostic differences within the same nodal (N) status have been
reported. Consequently, the International Association for the Study of Lung Cancer (IASLC) proposed to stratify
patients with limited nodal disease (pN1) from low (pN1a) to high (pN1b) nodal tumor burden. This study aimed
to validate the IASLC proposal in a large single-center surgical cohort of patients with pN1 NSCLC.
Material and Methods: Data from 317 patients with pN1 NSCLC treated between January 2012 and December
2016, were retrospectively analyzed. Associations between distribution of LN metastases and survival were
analyzed for different classification models—toward nodal extension (pN1a: one station involved; pN1b: mul-
tiple stations involved) and toward location (pN1 in the hilar [LN#10/11] or peripheral zone [LN#12-14]).
Results: Tumor-specific survival (TSS) in the entire pN1 cohort was 67.1% at five years. Five-year TSS rates for
pN1a and pN1b patients were comparable (67.6% vs. 66.5%, p=0.623). Significant survival differences from
pN1a to pN1b were observed only in patients with adenocarcinoma histology and completed adjuvant che-
motherapy (5-year TSS: pN1a, 80.4% vs. pN1b, 49.6%; p=0.005). TSS for LN metastases in the hilar zone/
peripheral zone or in both zones was 68.2% and 59.9%, respectively (p=0.068). In multivariate analysis,
adjuvant chemotherapy, squamous cell histology, and nodal disease limited to one zone nodal disease were
identified as independent beneficial prognostic factors (p < 0.05).
Conclusion: pN1 in only one region (hilar or lobar) was associated with better outcome than metastatic affection
of both regions after surgery and adjuvant therapy. A stratification towards single (pN1a) and multiple (pN1b)
N1-metastases was found of prognostic relevance only in adenocarcinoma. Prospective multicenter analysis of
prognostic subgroups in N1 NSCLC is required to evaluate its clinical impact for consideration in future TNM
classification.
1. Introduction
Lung cancer is one of the leading causes of death worldwide [1].
Approximately 80% of lung cancer patients are consistent with non-
small cell histology (NSCLC) [2]. The Tumor-Node-Metastasis (TNM)
system is used to classify and stratify patients by prognosis according to
tumor size (T), lymph node (LN) involvement (N) and presence of
distant metastases (M). Its actual valid 8th edition was implemented in
2016 using clinical information from 70,976 consecutive NSCLC pa-
tients treated between 1999 and 2010 in 16 countries [3]. In patients
with limited thoracic disease (non-stage IV), nodal metastases have
been repeatedly identified as a strong prognostic predictor [4,5]. The N
descriptor describes the extent of LN metastases and comprises three
categories: N1 (ipsilateral hilar or ipsilateral lobar LN metastases); N2
(ipsilateral mediastinal LN metastases; subcarinal LN metastases); and
N3 (contralateral hilar or mediastinal LN metastases; supraclavicular
LN metastases).
For N1-positive NSCLC, radical surgical treatment followed by ad-
juvant chemotherapy is recommended [6–9]. Tumor resection (at least
lobectomy) is accompanied by radical LN compartment dissection to
enable precise nodal staging and to plan stage-dependent adjuvant
treatment, thus improving survival [10–12]. Resected intra-thoracic
LNs are consecutively numbered following a commonly used LN map-
ping system that was introduced by Mountain and Dresler (M-D map) in
1997 and modified in 2009 [13].
To analyze possible prognostic differences within the same N1
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category, the IASLC nodal map distinguishes N1 nodes more precisely
into a hilar/interlobar zone (M-D map: levels 10/11), and a peripheral
zone (M-D map levels 12–14) [14]. The clinical relevance of further
sub-classification has been noted by several authors who found a
worsening prognosis from peripheral N1 (levels 12–14) to more cen-
trally affected N1 LN metastases (levels 10/11) [15,16].
The prognostic value of a more detailed subclassification of the N1
descriptor has been recently discussed by the IASLC in a proposal ad-
dressing the implementation of the revised 8th TNM-edition for NSCLC.
The adjusted pN1 cohort from the IASLC database comprises data from
3554 patients with completely resected NSCLC. A better outcome was
demonstrated for patients with N1 metastases in only a single level
(pN1a) compared with multiple-level N1 (pN1b) [17]. No precise in-
formation is available regarding histology, extent of tumor resection
(lobar/sublobar), and adjuvant (chemo) therapy. Moreover, European
data (applicable data only from Norway and Serbia) accounts for only
15% of all analyzed N1 patients (n=544).
The aim of our study, therefore, was to validate the different N1
subclassification systems proposed by the IASLC in a large European
cohort of pN1 patients. All patients underwent curative intent lung
cancer surgery in a single high-volume thoracic center in Germany
(Thoraxklinik Heidelberg, Heidelberg University, Heidelberg,
Germany). Associations between the distribution of pN1 LN-metastases
and survival were analyzed and compared with existing data.
2. Material and methods
Data from 484 consecutive surgical patients with pN1 NSCLC, who
were treated at the authors’ institution between January 2010 and
December 2016, were retrospectively reviewed. Patients treated with
neoadjuvant therapy and those who underwent only sublobar or in-
complete tumor resections were excluded. Furthermore, patients with a
histology other than adenocarcinoma or squamous-cell carcinoma, and
those who died independent of tumor progression within 90 days after
surgery were also excluded. Ultimately, 317 patients were eligible for
further analysis.
Preoperative standard workup in all patients included cardio-
pulmonary function tests according to individual risk profiles. All pa-
tients underwent rigid tracheobronchoscopy for endoscopic evaluation.
Distant metastases were ruled out using abdominal, bone, and brain
sectional imaging, and, in more recent cases by PET-CT. Endobronchial
ultrasound and transbronchial needle aspiration were routinely used for
invasive mediastinal nodal staging. Inconclusive results (especially in
N2 compartment) were reevaluated by surgical standard mediastino-
scopy upfront surgery. Tumor staging of all patients was performed
following the 7th edition of the TNM-classification system, which was
valid during the complete treatment period. All patients were discussed
in the authors’ multidisciplinary tumor board. Surgical procedures in-
cluded anatomical resections depending on tumor extent (such as lo-
bectomy, bilobectomy, and pneumonectomy). Systematic radical com-
partment dissection of mediastinal (N2) and hilar/interlobar LNs (N1)
was an integral part of each procedure.
2.1. LN assessment
All dissected intrathoracic LNs were primary allocated to hilar
(#10), interlobar (#11), and lobar (#12-14) compartments according
to the MeD map (for non-Asian patients) [13]. Retrospectively, meta-
static nodes were classified into potential prognostic subgroups:
- Classification by nodal tumor burden: subdivision to pN1a (only
one compartment involved) and pN1b (more than one compartment
involved) according to the most recent IASLC proposal [17].
- Classification by location of metastatic node: Assignment to hilar
zone (nodes #10, #11) and peripheral zone (nodes #12-14) as defined
in the IASLC map [14].
2.2. Staging, adjuvant therapy and follow-up
All tumors were classified according to the 7th TNM-edition that was
valid at time of diagnosis. Restaging of all tumors towards the recent 8th
edition was internally performed in order to evaluate associated
changes of prognostic factors. Nevertheless, survival data was calcu-
lated following the 7th edition in order to avoid a mismatch between the
date of treatment decision and validity of the connected TNM-edition.
All patients were discussed in the multidisciplinary tumor board for
adjuvant therapy before discharge. According to postoperative re-
covery, constitution, and risk profile, all patients were recommended to
undergo 4 cycles of adjuvant platinum-based doublet chemotherapy.
Follow-up visits were scheduled at the outpatient service every 3
months. Recurrence of disease resulted in whole-body restaging and
interdisciplinary discussion. Suspicious recurrent lesions were further
classified according to their localization (intrathoracic only, distant
only, or multiple).
2.3. Survival analysis
Tumor specific survival (TSS) was defined as the time from the date
of surgery to the date of tumor-related death or last follow-up in cen-
sored, alive patients. Disease-free survival (DFS) was defined as the date
of surgery to the date of first detection of recurrence. To analyze
prognostic differences within pN1 patients undergoing standard post-
operative therapy, univariate survival calculation focused on patients
who underwent complete adjuvant chemotherapy.
Data were collected and analyzed using SPSS version 25 (IBM
Corporation, Armonk, NY, USA). Cumulative survival was calculated
using the Kaplan-Meier product method, while the log rank-test was
used to calculate univariate differences, and the Cox-regression model




Data from 317 patients (102 females [32.2%]), with a mean (± SD)
age of 64.9 ± 9.7 years were retrospectively analyzed. The majority of
tumors were upper lobe tumors (n= 191 [60.3%]), solely located on
the right (n=171 [53.9%]). Lobectomies were performed in 207
(65.3%) patients, pneumonectomies in 89 (28.1%), and bilobectomies
in 21 (6.6%). Extensions to bronchial sleeve resections were performed
in 52 (16.4%) patients. T-stage was pT1 in 32 (10.1%) patients, pT2 in
150 (47.3%), pT3 in 90 (28.4%), and pT4 in 45 (14.2%). Moreover, 182
(57.4%) patients were classified as stages IIA/B and 135 (42.6%) pa-
tients were classified as stage IIIA. There were 170 (53.6%) squamous
cell carcinomas and 147 (46.4%) adenocarcinomas. The major pre-
dominant adenocarcinoma subtypes were as follows: solid (n=51
[34.7%]), acinar (n=42 [28.6%]), and papillary (n=31 [21.1%])
(Table 1).
3.2. LN assessment
At initial clinical staging, 105 patients were classified cN0 and 43
patients were classified cN2. cN1 was stated in 169 patients (53.3%).
Thus, nodal upstaging (cN0 but pN1) was observed in 33.1%, down-
staging (cN2 but pN1) in 13.6%.
Pathological N1a status (one compartment involved) was found in
207 (65.3%) patients and pN1b (more than one compartment involved)
in 110 (34.7%). Of all 207 pN1a patients, 41 (12.9%) exhibited me-
tastases in LN #10, 52 (16.4%) in LN #11, and 114 (36.0%) in LNs
#12/13/14. Following IASLC zonal classification, nodal metastases
were located exclusively in the hilar (# 10/11) or peripheral zone
(#12,13,14) in 93 (29.3%) and 149 (47.0%) patients, respectively. N1
F. Eichhorn, et al. Lung Cancer 138 (2019) 95–101
96
44
metastases in both hilar and peripheral zones were found in 75 (23.7%)
patients.
3.3. Adjuvant treatment and tumor recurrence
A total of 198 (62.4%) patients underwent adjuvant platinum-based
chemotherapy. In 119 (37.5%) patients, adjuvant chemotherapy was
not administered. Reasons included comorbidity or questionable evi-
dence with regard to patient age (n= 87 [73.1%]), patient refusal
(n= 27 [22.6%]), or progressive disease in the meantime (n= 5
[4.2%]). At the time of last analysis (January 2019), 197 patients
(62.1%) were free of recurrence. The calculated DFS at five years was
56.4%. Tumor recurrence was detected in 120 (37.9%) patients, 70 of
whom developed distant metastases.
3.4. Long-term survival and prognostic factors
Of the 317 patients, 217 (68.5%) were alive in January 2019 after a
median follow up of 35 months. The TSS rate at 5 years was 67.1%
(Fig. 1). According to T-category, five-year TSS was 91% for T1, 74%
for T2, 53% for T3, and 57% for T4 tumors. These differences were
statistically significant (i.e., p < 0.05), except for the comparison of T1
and T2 (p=0.075). Comparison of clinical and pathological nodal
status revealed no prognostic benefit for incidental finding of N1 (cN0
but pN1 vs. cN1 and pN1, 62.3% vs. 72.1% at five years, p= 0.277).
Conclusively, stages IIA/IIB (T1N1/T2N1) were associated with
significantly better survival than stage IIIA (T3N1/T4N1) (76.6% vs.
53.8%, respectively; p= 0.001) (Fig. 2). Squamous cell carcinoma was
associated with a slightly higher survival rate at five years (70%) than
adenocarcinoma (64%); however, the difference was not statistically
significant (p=0.35). Survival significantly improved in N1 patients
who underwent adjuvant chemotherapy (TSS 72% vs. 57% at 5 years;
p= 0.003).
Comparable survival was observed when all 317 N1 patients were
separated into N1a and N1b groups (5-year TSS 67.6% vs. 66.5%;
p=0.623).
In univariate subgroup analysis of patients treated with adjuvant
chemotherapy, survival differences (comparing pN1a with pN1b) were
found only in patients with adenocarcinoma histology (5-year TSS
80.4% [pN1a] vs. 49.6% [pN1b]; p= 0.005) (Fig. 3), not in those with
squamous cell carcinoma (5-year TSS 69.6% [pN1a] vs. 79.7% [pN1b];
p= 0.58). For patients who did not undergo adjuvant therapy, strati-
fication according to the pN1a/pN1b model appeared to have no
prognostic impact (adenocarcinoma: 5-year TSS, 47.9% [pN1a] vs.
56.4% [pN1b], p= 0.82; squamous cell carcinoma: 5-year TSS, 62.2%
[pN1a] vs. 69.1 [pN1b], p= 0.96).
Following a location based nodal subgrouping (only hilar zone or
peripheral zone), no prognostic difference in between these two groups
was observed (74.2% vs. 69.5% at five years p= 0.849). Patients with
metastases in both the hilar and peripheral zone demonstrated a trend
toward poorer survival than those with only one zone affected (hilar or
peripheral zone only: 68.2%; both zones: 59.9%, p=0.068) (Fig. 4A).
Univariate analysis according to histological subtype revealed that this
classification model (toward zones) had a significant influence on sur-
vival in patients with adenocarcinoma (p= 0.001) but not in those
with squamous cell carcinoma (p=0.806) (Fig. 4B and C).
Multivariate analysis of pN1-patients showed that adenocarcinoma
histology, high tumor stage, high nodal burden (affection of hilar and
peripheral zone) and absence of adjuvant chemotherapy were asso-
ciated with worse survival compared to the comparators (Table 2).
Classification following the pN1a/pN1b model had no significant
prognostic impact in multivariate analysis, nevertheless a trend towards
better survival for patients with single metastases (pN1a) was observed.
4. Discussion
A total of 317 patients with N1-positive NSCLC, who underwent
curative intent surgical therapy, were retrospectively analyzed.
Involvement of multiple nodal locations (pN1b) and advanced regional
nodal extension (i.e., LN metastases in the central hilar and peripheral
zone) were associated with poor prognosis in patients with adeno-
carcinoma histology.
The individual course of disease in patients with non-metastatic
cancer is strongly determined by the presence of LN metastases, re-
flected in different N descriptors in the TNM-staging system [14].
Nevertheless, prognostic differences have been described within pa-
tients stratified according to the same N category [18]. Saji et al. ana-
lyzed 689 surgical patients and identified a low number of nodal me-
tastases (1–3 LN metastases) as a beneficial prognostic factor.
Moreover,> 4 LN metastases in the N1 compartment was associated
with even poorer survival than limited (1–3 LN metastases) pN2-stage.
However, only 91 pN1 patients were analyzed [19]. Analysis of the
IASLC pN1 cohort also revealed a decrease in survival the more meta-
static N1-nodes exist. The authors, therefore, proposed to subdivide
pN1 positive NSCLC patients into pN1a (a single station involved, 58%
alive at 5 years) and pN1b (multiple stations involved, 50% alive at 5
years) in future TNM-classifications [17]. Analysis of our patients
confirmed differences in survival between patients with pN1a and pN1b
LN involvement; nevertheless, these were statistically significant only
in those with adenocarcinoma histology.


















Tumor Stage (UICC 7)
Stages IIA/IIB 182 (57.4)
Stage IIIA 135 (42.6)
Tumor Stage (UICC 8)
Stage IIB 138 (43.5)
Stage IIIA 179 (56.6)
Nodal subdivision (stations involved)
pN1a (one station involved) 207 (65.3)
pN1b (multiple stations involved) 110 (34.7)
Nodal subdivision (distribution to zones)
Hilar zone only (nodes #10/11) 93 (29.3)
Peripheral zone only (nodes #12-14) 149 (47.0)
Both zones involved 75 (23.7)
Histology





Recurrence at Follow up
No recurrence 197 (62.1)
Local intrathoracic 31 of 120
Single distant 70 of 120
Multiple 19 of 120
Tumor-specific survival (1-/ 3-/ 5-year) 90.5%/73.4%/67.1%
Squamous cell carcinoma 90.8/75.0%/69.8%
Adenocarcinoma 89.4/71.6%/63.9%
Disease free survival (5-year) 56.4%
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metastatic patterns, it is important to note that LN staging varies be-
tween Asia and western/European countries. Discrepancies among the
“Naruke” map (Asia) [20] and the “Mountain-Dresler” modification
(rest of the world) [13] harden consistent allocation to N1- and N2-level
compartments (e.g., inferior border of the main stem bronchus: Naruke:
N1, Mountain-Dresler: N2). These variations may explain the striking
deviation of 5-year survival rates in European (36%) and Asian patients
(61%) found in the IASLC database. Moreover, European information is
under-represented, with only 544 pN1 patients from Norway and Serbia
analyzed. In contrast, pN1 data from 2496 Asian patients, representing
Fig. 1. Tumor specific survival at 5 years was 67.1% for the entire cohort (317 patients, incomplete and sublobar resections excluded; histology other than squamous-
cell carcinoma or adenocarcinoma excluded). TSS: Tumor specific survival.
Fig. 2. Tumor stage was clearly identified as an independent factor with influence on survival irrespective of tumor histology and adjuvant therapy. Survival was
significantly worse in more advanced disease (stage IIIA vs. IIA/B, p=0.001). TSS: Tumor specific survival.
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65% of all worldwide pN1-patients, were found to be eligible for eva-
luation [17].
We believe that our analysis can serve as an important addition to
the existing data. All pN1-patients in our series were classified ac-
cording to the MeD system, in which the observed TSS of the entire
group was 67.1% at 5 years. Interestingly, five-year survival in patients
without adjuvant therapy was still calculated to be 57%, which
is> 20% higher than the reported survival rate of the European IASLC
cohort, reaching 36%. The observed discrepancy in the survival rates is
difficult to explain. The large data set and its retrospective character-
istics may result in incomprehensible information regarding the ad-
juvant therapy regimen. Furthermore, frequency and thoroughness of
follow-up-intervals affect the latency to detection of recurrent disease
and, therefore, influence survival. Third, individual differences re-
garding the invasiveness of intraoperative mediastinal nodal staging
(from nodal sampling to complete compartment dissection) are prog-
nostically relevant. A more restrictive nodal examination during sur-
gery may underestimate true nodal extent, thus influencing subsequent
therapy and course of the disease [11,21–23].
To overcome prognostic variations caused by different classification
systems or discrepancies in intraoperative nodal allocations, Rusch
et al. proposed to group LNs into “zones,” as described in a validated
international IASLC map [14]. Following this model, we also found that
N1 metastases in more than one zone (i.e., hilar and peripheral) were
associated with poorer prognosis compared with single-zone involve-
ment. However, in our series, these findings were identified as a sig-
nificant prognostic factor only in adenocarcinoma, not in squamous cell
carcinoma. A correlation between distribution patterns of N1 LNs and
survival has been repeatedly demonstrated [24,25]; nevertheless, dif-
ferences between distinct histological subtypes were not observed. In
large surgical NSCLC populations, controversial results with regard to
prognostic differences favoring either adenocarcinoma or squamous
cell carcinoma have been reported [26–29]. Notably, these series and,
as mentioned above, the IASLC database, consist of a large Asian study
population. These harbor a significantly higher incidence of lung
adenocarcinoma than the western or European countries, which must
be taken into account during data interpretation [27,30,31]. Our series
supports recent results in Caucasian pN1 NSCLC [32–34] and may serve
as a valuable contribution to the existing European source data in the
IASLC database. Nevertheless, the clinical impact of these findings re-
mains debatable as long as prospective multicenter analysis of in-
dividual patient data has not been implemented. Currently, except a
partial influence of the T-descriptor, adjuvant treatment decision
merely follows the pathological N-status irrespective of the individual
nodal burden. Consequently, upcoming revisions of the TNM-system
should strongly take into account nodal subgroups in order to pro-
spectively evaluate possibly relevant changes in treatment or follow-up
strategies. In the light of recent developments in targeted and im-
munotherapy in advanced lung cancer, the relevance of novel ther-
apeutic approaches should be underlined in future prospective clinical
workup of nodal subgroups with prognostic relevance.
We analyzed a large surgical single-center cohort of patients with
N1-positive NSCLC, and identified adenocarcinoma histology and ad-
vanced nodal extent (pN1b, multiple N1 zones affected) as poor prog-
nostic factors. Our results support the recent survival data from pN1
patients housed in the IASLC database. For future analysis, our carefully
selected data could serve as an important addition to the sparse pre-
vious European contribution to the IASLC database. We suggest that
upcoming proposals for future TNM-classifications should assess the
value of a more detailed stratification of N1 patients toward histology,
nodal extent, and anatomical compartment distribution.
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Fig. 3. Dividing pN1-patients into pN1a and pN1b was found to have prognostic impact in one subgroup of our patients: significant difference in survival could be
demonstrated in patients with adenocarcinoma histology and complete adjuvant chemotherapy. TSS: Tumor specific survival.
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Fig. 4. Survival analysis with respect to the location based model (hilar vs. peripheral zone, according to IASLC [14]). A tendency towards poorer prognosis was
found in patients with multiple nodal zones involved (A). Univariate analysis after stratification towards histological subtype showed significant poorer survival in
patients with adenocarcinoma (B, p= 0.001). No difference was found in patients with squamous cell carcinoma (C, p=0.806).
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